Alan Ezekowitz Sells 18,000 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the sale, the director owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC opened at $3.64 on Thursday. The business’s 50-day simple moving average is $5.48 and its 200 day simple moving average is $8.12. The company has a market cap of $242.53 million, a P/E ratio of -3.17 and a beta of 3.01. Fulcrum Therapeutics, Inc. has a one year low of $2.83 and a one year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. Analysts predict that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Suvretta Capital Management LLC raised its stake in shares of Fulcrum Therapeutics by 21.9% in the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock valued at $74,206,000 after purchasing an additional 1,180,111 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in Fulcrum Therapeutics by 8.9% in the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after buying an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Fulcrum Therapeutics by 53.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after buying an additional 1,589,000 shares during the last quarter. Braidwell LP raised its stake in Fulcrum Therapeutics by 1,294.7% during the fourth quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock valued at $34,622,000 after buying an additional 2,841,734 shares in the last quarter. Finally, Siren L.L.C. raised its stake in Fulcrum Therapeutics by 20.5% during the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after buying an additional 400,000 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FULC. Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price target for the company. in a report on Tuesday, June 2nd. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 target price on Fulcrum Therapeutics in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $8.20.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.